• Review and approve a peer group of companies to be used for marketplace trend analysis and to assess the competitiveness of the Company’s total compensation opportunities for executive officers. 2 • Review and approve corporate goals and objectives relevant to the Chief Executive Officer’s compensation; in conjunction with the evaluation conducted by the Board (including as described in the Company’s Corporate Governance Guidelines), evaluate the Chief Executive Officer’s performance annually in light of these goals and objectives; and determine and recommend to the independent members of the Board for their determination and approval the Chief Executive Officer’s compensation level based on this evaluation and considering comparable market data provided by an independent compensation consultant. • In determining the long-term incentive component of the Chief Executive Officer’s compensation, consider the Company’s performance and relative shareholder return, the value of similar incentive awards to chief executive officers at comparable companies, and the awards given to the Chief Executive Officer in the past. • Review and approve the compensation of other executive officers of the Company, including benefits and perquisites, taking into consideration the Company’s performance, comparable market data, the performance of each executive officer, and such other factors as may, in the Committee’s discretion, be appropriate. • In evaluating and making recommendations regarding, or determining and approving, executive officer compensation, the Committee shall consider the results of the most recent shareholder advisory vote on executive compensation (“Say on Pay Vote”) required by Section 14A of the Exchange Act. • Make recommendations to the Board with respect to the approval of incentive compensation plans for executive officers and all equity-based plans. • For annual (or other short term) incentive plans: o Review and approve annual incentive plans (including performance criteria, target awards, payout criteria and similar award design items applicable under such plans) that are applicable to executive officers and any Company officers reporting directly to the Chief Executive Officer. o Review and approve attainment levels and payments to executive officers and any other Company officers reporting directly to the Chief Executive Officer. • For long-term and equity-based incentive plans: o Review and approve the performance criteria, target awards, payout criteria and similar award design items for recipients of grants and awards under the plans. o Review and approve grants, awards, and attainment levels, including equity-based grants, to recipients of grants and awards under such plans. o Review and approve payments for performance-based grants and awards to executive officers and any other Company officers reporting directly to the Chief Executive Officer, as applicable, under such plans. • Administer the Company’s equity-based incentive compensation plans and other plans adopted by the Board that contemplate administration by the Committee. • Review and approve the terms of all employment agreements, executive severance plan and agreements, management continuity agreements and change in control agreements for elected officers. • Approve the adoption and amendment of Company stock ownership guidelines and annually review compliance with these guidelines. 3 Non-employee Director Compensation. • Review the compensation of non-employee directors and make recommendations to the Board regarding changes to existing compensation levels. • Review and recommend to the Board for its approval equity-based grants and awards to non- employee directors under the Company’s equity-based plans and annually review compliance with Company stock ownership guidelines.

在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。

在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。

COMMITMENT TO RECORD RETENTION Formulations and yarn samples of every production lot are archived and retained for 2 to 5 years to ensure traceability.

Magatartási kódexünk 2023 Tartalomjegyzék Üzenet a CEO-tól 1 Víziónk és stratégiánk 2 Alapvető és személyes értékek 2 Magatartási kódexünk Az etikus magatartás irányelvei 4 Személyes értékek 4 Problémamegoldás és a szabálysértések jelentése 6 Etikai forródrót 6 Tilos a megtorlás! Patterson, elnök-vezérigazgató 2 Tartalomjegyzék Víziónk és stratégiánk Jövőkép Az Avientnál speciális és fenntartható anyagmegoldásokat hozunk létre, amelyek az ügyfelek kihívásait lehetőségekké alakítják, és új termékeket hívnak életre egy jobb világ érdekében. Kövesse ezt a két szabályt: 1. 1. ne használjon fel fontos nem nyilvános információkat saját haszonszerzés céljából; és 2. 2. az ilyen információt ne ossza meg olyan személlyel, akinek nem kell feltétlenül tudnia róla az Avient vállalatnál végzett munkájából kifolyólag.

Cập nhật: Tháng 2 năm 2021 Chính sách toàn cầu về Chống độc quyền của Avient Nội dung Hướng dẫn Tuân thủ 1 Tổng quan về Chính sách 1 Tổng quan về các Luật chống độc quyền của Hoa Kỳ 2 Vi phạm pháp luật chống độc quyền 3 Các lĩnh vực quan ngại tiềm ẩn về chống độc quyền 3 Kết luận 6 Báo cáo các vi phạm có thể xảy ra 7 Đường dây nóng về Đạo đức của Avient 7 Bảo vệ khỏi sự trả đũa 7 Danh mục kiểm tra Chống độc quyền 8 Tham khảo nhanh: NHỮNG ĐIỀU NÊN LÀM và KHÔNG NÊN LÀM về Chống độc quyền 10 Hướng dẫn Tuân thủ Avient cam kết thúc đẩy cạnh tranh công bằng và doanh nghiệp tự do trên thị trường. Bất cứ khi nào bạn dự kiến tham gia vào các hoạt động nhạy cảm chống độc quyền có thể có ảnh hưởng trong hoặc ngoài Hoa Kỳ, bạn nên tham khảo trước với phòng Pháp chế của Avient. 2 Nội dung Chính sách Chống độc quyền Sửa đổi Năm 2021 Bạn có biết? Tránh tiếp xúc không cần thiết với đối thủ cạnh tranh. 2.

Dial-in number: Dial-in number:

Dial-in number:   Dial-in number:   

Dial-in number:   Dial-in number:   

Dial-in number:  Dial-in number: